• LAST PRICE
    17.7200
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    15.9500/ 10
  • Ask / Lots
    18.1500/ 4
  • Open / Previous Close
    17.8400 / 17.7200
  • Day Range
    Low 17.7000
    High 17.9600
  • 52 Week Range
    Low 16.0000
    High 29.1150
  • Volume
    41,635
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 17.72
TimeVolumeANIK
09:32 ET12417.84
09:39 ET95017.96
09:44 ET20017.79
09:50 ET10017.845
10:00 ET30017.91
10:09 ET40017.79
10:11 ET60017.78
10:24 ET10017.77
10:26 ET10017.83
10:31 ET20017.81
10:38 ET11917.81
10:40 ET70017.77
10:42 ET50017.78
11:14 ET30017.74
11:30 ET19717.7011
11:56 ET30017.81
12:01 ET150017.8
12:08 ET10017.83
12:24 ET20017.81
12:30 ET10017.8
12:39 ET38817.8
12:51 ET20017.76
12:55 ET10017.7
12:57 ET146517.73
01:00 ET1914217.72
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesANIK
Anika Therapeutics Inc
259.5M
-2.7x
---
United StatesCERS
Cerus Corp
338.0M
-17.2x
---
United StatesLUNG
Pulmonx Corp
255.1M
-4.4x
---
United StatesINFU
InfuSystem Holdings Inc
188.4M
132.1x
---
United StatesACU
Acme United Corp
165.9M
9.0x
+30.24%
United StatesSGHT
Sight Sciences Inc
202.0M
-3.9x
---
As of 2024-12-01

Company Information

Anika Therapeutics, Inc. is a global joint preservation company. The Company creates and delivers advancements in early intervention orthopedic care, including in the areas of osteoarthritis (OA) pain management, regenerative solutions, and sports medicine. It is focused on developing, manufacturing and commercializing products on its hyaluronic acid (HA), technology platform. Its OA Pain Management product family consists of Monovisc and Orthovisc, its injectable, HA, OA Pain Management offerings are indicated to provide pain relief from osteoarthritis conditions; and Cingal, its novel, next generation, single-injection OA Pain Management product consisting of its proprietary cross-linked HA material combined with a steroid. Its Joint Preservation and Restoration product family consists of its portfolio of orthopedic regenerative solutions products utilizing HA, including Integrity, its new hyaluronic acid-based scaffold for rotator cuff and other tendon repairs.

Contact Information

Headquarters
32 Wiggins AveBEDFORD, MA, United States 01730-2315
Phone
781-457-9000
Fax
781-305-9720

Executives

Independent Chairman of the Board
John Henneman
President, Chief Executive Officer, Director
Cheryl Blanchard
Executive Vice President, Chief Financial Officer, Treasurer
Stephen Griffin
Chief Operations Officer, Senior Vice President
Anne Nunes
Executive Vice President, General Counsel, Secretary
David Colleran

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$259.5M
Revenue (TTM)
$164.2M
Shares Outstanding
14.6M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.89
EPS
$-6.64
Book Value
$14.48
P/E Ratio
-2.7x
Price/Sales (TTM)
1.6
Price/Cash Flow (TTM)
---
Operating Margin
-58.90%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.